Attached files

file filename
10-Q - FORM 10-Q - ACHILLION PHARMACEUTICALS INCd230843d10q.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex311.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex322.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex312.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex321.htm
EXCEL - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR15.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR17.htm
v2.3.0.15
Marketable Securities
9 Months Ended
Sep. 30, 2011
Marketable Securities [Abstract] 
Marketable Securities

7. Marketable Securities

The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures, for financial assets and liabilities measured on a recurring basis which requires disclosure that establishes a framework for measuring fair value and expands disclosures in the financial statements. The guidance requires that fair value measurements be classified and disclosed in one of the three categories:

Level 1: Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date;

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; or

Level 3: Unobservable inputs.

The fair value of the Company's marketable securities of $66,612 and $29,827 as of September 30, 2011 and December 31, 2010, respectively, is valued based on level 2 inputs. The Company's investments consist mainly of U.S government and agency securities, government sponsored bond obligations and certain other corporate debt securities. Fair value is determined based upon quoted market prices; however, due to lack of sufficiency of transactions and trading volume, the Company has assessed these as level 2 within the fair value hierarchy of ASC 820. The Company classifies its entire investment portfolio as available for sale as defined in ASC 320, Debt and Equity Securities. Securities are carried at fair value with the unrealized gains (losses) reported as a separate component of stockholders' equity within accumulated other comprehensive income.

The unrealized (loss) gain from marketable securities was $(43) and $2 at September 30, 2011 and December 31, 2010, respectively.

As of September 30, 2011 and December 31, 2010, none of the Company's investments were determined to be other than temporarily impaired.